DE69929019D1 - Mu-1, ein mitglied der zytokinrezeptor-familie - Google Patents

Mu-1, ein mitglied der zytokinrezeptor-familie

Info

Publication number
DE69929019D1
DE69929019D1 DE69929019T DE69929019T DE69929019D1 DE 69929019 D1 DE69929019 D1 DE 69929019D1 DE 69929019 T DE69929019 T DE 69929019T DE 69929019 T DE69929019 T DE 69929019T DE 69929019 D1 DE69929019 D1 DE 69929019D1
Authority
DE
Germany
Prior art keywords
receptor family
cytokin
cytokin receptor
disclosed
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69929019T
Other languages
English (en)
Other versions
DE69929019T2 (de
Inventor
Debra Donaldson
Michelle Ungar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21908554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69929019(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of DE69929019D1 publication Critical patent/DE69929019D1/de
Publication of DE69929019T2 publication Critical patent/DE69929019T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69929019T 1998-03-17 1999-03-17 Mu-1, ein mitglied der zytokinrezeptor-familie Expired - Lifetime DE69929019T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40005 1998-03-17
US09/040,005 US6057128A (en) 1998-03-17 1998-03-17 MU-1, member of the cytokine receptor family
PCT/US1999/005854 WO1999047675A1 (en) 1998-03-17 1999-03-17 Mu-1, member of the cytokine receptor family

Publications (2)

Publication Number Publication Date
DE69929019D1 true DE69929019D1 (de) 2006-01-26
DE69929019T2 DE69929019T2 (de) 2006-08-03

Family

ID=21908554

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69929019T Expired - Lifetime DE69929019T2 (de) 1998-03-17 1999-03-17 Mu-1, ein mitglied der zytokinrezeptor-familie

Country Status (9)

Country Link
US (3) US6057128A (de)
EP (4) EP0994947B1 (de)
JP (3) JP2001527423A (de)
AT (1) ATE313626T1 (de)
AU (1) AU758824B2 (de)
DE (1) DE69929019T2 (de)
DK (1) DK0994947T3 (de)
ES (1) ES2253879T3 (de)
WO (1) WO1999047675A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
EP1088831A4 (de) * 1998-06-24 2003-01-02 Chugai Pharmaceutical Co Ltd Hämopoietin-rezeptor proteine
AU5104799A (en) * 1998-08-04 2000-02-28 Regeneron Pharmaceuticals, Inc. Novel orphan cytokine receptors
EA201001190A1 (ru) * 1998-09-23 2011-04-29 Займодженетикс, Инк. Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6803451B2 (en) 1998-09-23 2004-10-12 Zymogenetics, Inc. Cytokine receptor zalpha11 polypeptides
AU2004203069B2 (en) * 1998-09-23 2008-06-12 Zymogenetics Inc. Cytokine Receptor Zalpha11
CN101575377B (zh) * 1999-03-09 2012-12-26 津莫吉尼蒂克斯公司 作为zalpha受体之配体的人细胞因子及其用途
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
AU5142300A (en) * 1999-05-18 2000-12-05 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
US20020090680A1 (en) * 1999-05-18 2002-07-11 Millennium Pharmaceuticals, Inc. Novel IL-9/IL-2 receptor-like molecules and uses thereof
DE60141234D1 (de) * 2000-04-05 2010-03-18 Zymogenetics Inc Löslicher Zytokinrezeptor zalpfa11
DE60124954T2 (de) * 2000-05-11 2007-09-20 Genetics Institute, LLC, Cambridge Mu-1, ein mitglied der cytokine rezeptor familie
JP2005508915A (ja) * 2001-10-04 2005-04-07 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー インターロイキン２１受容体活性を調節する方法および組成物
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
EP2377549A1 (de) * 2002-06-07 2011-10-19 ZymoGenetics, Inc. Verwendung von IL-21 zur Behandlung von Virusinfektionen
BR0312738A (pt) * 2002-07-15 2007-06-26 Wyeth Corp processos e composições para a modulação do desenvolvimento e da função de células t auxiliares (th)
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
AU2003302250B2 (en) 2002-12-13 2009-08-27 Zymogenetics, Inc. IL-21 production in prokaryotic hosts
JP4914209B2 (ja) * 2003-03-14 2012-04-11 ワイス ヒトｉｌ−２１受容体に対する抗体および該抗体の使用
KR20060015482A (ko) * 2003-03-21 2006-02-17 와이어쓰 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
WO2005030196A2 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
CA2566745A1 (en) * 2004-05-20 2005-12-01 Zymogenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy
US20070111941A1 (en) * 2004-06-09 2007-05-17 Zymogenetics, Inc. Cytokine receptor zalpha11
BRPI0514138A (pt) * 2004-08-05 2008-05-27 Wyeth Corp método para tratar, melhorar, ou prevenir um distúrbio, proteìna de fusão, vetor, célula hospedeira recombinante, método para produzir uma proteìna de fusão, composição farmacêutica, e, métodos para transplantar/enxertar um órgão, tecido, célula ou grupo de células em um indivìduo mamìfero, e para tratar, prevenir ou melhorar rejeição de transplante/enxerto em um receptor de transplante/enxerto mamìfero
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
US7592427B2 (en) * 2005-11-28 2009-09-22 Zymogenetics, Inc. Antibodies to IL-21 receptor
EP2567973B1 (de) * 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21-Antagonisten
KR101615215B1 (ko) 2007-12-07 2016-04-25 지모제넥틱스, 인코포레이티드 항-사람 ｉｌ-21 단클론성 항체
AR071885A1 (es) * 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
EP2296689A1 (de) * 2008-05-23 2011-03-23 Wyeth LLC Behandlungsverfahren unter verwendung von bindungsproteinen des interleukin-21-rezeptors

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
EP0325224B1 (de) 1988-01-22 1996-07-31 ZymoGenetics, Inc. Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5216131A (en) 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CN1117155C (zh) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU2326097A (en) 1996-03-13 1997-10-01 Zymogenetics Inc. Cytokine-receptor expressed in testis cells
WO1997047742A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1997047741A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
EP0812913A3 (de) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR1 Rezeptor, ein Rezeptor der Zytokinrezeptor-Familie
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
AUPO224696A0 (en) 1996-09-11 1996-10-03 Amrad Operations Pty. Limited A novel haemopoietin receptor and genetic sequences encoding same
JP2001508309A (ja) * 1997-01-16 2001-06-26 ジェネティックス・インスチチュート・インコーポレーテッド ヘマトポイエチン受容体スーパーファミリーのメンバー
US20010025022A1 (en) 1997-11-26 2001-09-27 Kikly Kristine Kay Hnovilr
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6509057B2 (en) * 1998-04-01 2003-01-21 Sumitomo Osaka Cement, Co., Ltd. Antibacterial, antifungal or antialgal article and process for producing same
EP1088831A4 (de) 1998-06-24 2003-01-02 Chugai Pharmaceutical Co Ltd Hämopoietin-rezeptor proteine
AU5104799A (en) 1998-08-04 2000-02-28 Regeneron Pharmaceuticals, Inc. Novel orphan cytokine receptors
US6576744B1 (en) 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6803451B2 (en) 1998-09-23 2004-10-12 Zymogenetics, Inc. Cytokine receptor zalpha11 polypeptides
EA201001190A1 (ru) 1998-09-23 2011-04-29 Займодженетикс, Инк. Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков
EP1124851A1 (de) 1998-11-06 2001-08-22 Smithkline Beecham Corporation Hnovilr
CN101575377B (zh) 1999-03-09 2012-12-26 津莫吉尼蒂克斯公司 作为zalpha受体之配体的人细胞因子及其用途
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
AU5142300A (en) 1999-05-18 2000-12-05 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
US20020090680A1 (en) 1999-05-18 2002-07-11 Millennium Pharmaceuticals, Inc. Novel IL-9/IL-2 receptor-like molecules and uses thereof
EP1230368A2 (de) 1999-11-18 2002-08-14 Schering Corporation Rezeptorproteine aus säugetieren; verwandte reagenzien und verfahren
EP2248828A1 (de) 1999-12-23 2010-11-10 ZymoGenetics, Inc. Verfahren zur Behandlung von Entzündungen
DE60141234D1 (de) 2000-04-05 2010-03-18 Zymogenetics Inc Löslicher Zytokinrezeptor zalpfa11
DE10019727A1 (de) * 2000-04-20 2001-10-25 Alcatel Sa Netzwerkserver
DE60124954T2 (de) 2000-05-11 2007-09-20 Genetics Institute, LLC, Cambridge Mu-1, ein mitglied der cytokine rezeptor familie
JP2002157737A (ja) * 2000-05-12 2002-05-31 Tdk Corp 光記録方法および光記録媒体
US6680563B2 (en) * 2001-06-27 2004-01-20 Thomson Licensing S.A. Color picture tube having a low expansion tension mask attached to a higher expansion frame
US6719302B2 (en) * 2001-07-02 2004-04-13 Vertex, Inc. Symmetrical gasket for a pipe joint with increased surface contact
JP2005508915A (ja) 2001-10-04 2005-04-07 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー インターロイキン２１受容体活性を調節する方法および組成物
DK1451322T3 (da) 2001-11-05 2010-02-01 Zymogenetics Inc Il-21-antagonister
US20040016010A1 (en) 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
BR0312738A (pt) 2002-07-15 2007-06-26 Wyeth Corp processos e composições para a modulação do desenvolvimento e da função de células t auxiliares (th)
JP4914209B2 (ja) 2003-03-14 2012-04-11 ワイス ヒトｉｌ−２１受容体に対する抗体および該抗体の使用
KR20060015482A (ko) 2003-03-21 2006-02-17 와이어쓰 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
AU2005244942A1 (en) 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
BRPI0514138A (pt) 2004-08-05 2008-05-27 Wyeth Corp método para tratar, melhorar, ou prevenir um distúrbio, proteìna de fusão, vetor, célula hospedeira recombinante, método para produzir uma proteìna de fusão, composição farmacêutica, e, métodos para transplantar/enxertar um órgão, tecido, célula ou grupo de células em um indivìduo mamìfero, e para tratar, prevenir ou melhorar rejeição de transplante/enxerto em um receptor de transplante/enxerto mamìfero
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2009100035A2 (en) 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
EP2296689A1 (de) 2008-05-23 2011-03-23 Wyeth LLC Behandlungsverfahren unter verwendung von bindungsproteinen des interleukin-21-rezeptors
AR071885A1 (es) 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21

Also Published As

Publication number Publication date
EP1681348A1 (de) 2006-07-19
US6057128A (en) 2000-05-02
US20080167241A1 (en) 2008-07-10
EP0994947A1 (de) 2000-04-26
JP2013188214A (ja) 2013-09-26
EP1688495A1 (de) 2006-08-09
AU3009399A (en) 1999-10-11
JP2001527423A (ja) 2001-12-25
DE69929019T2 (de) 2006-08-03
ATE313626T1 (de) 2006-01-15
ES2253879T3 (es) 2006-06-01
JP2010057489A (ja) 2010-03-18
US7994292B2 (en) 2011-08-09
EP0994947B1 (de) 2005-12-21
AU758824B2 (en) 2003-04-03
US20100130729A1 (en) 2010-05-27
WO1999047675A1 (en) 1999-09-23
DK0994947T3 (da) 2006-04-18
EP2228448A1 (de) 2010-09-15
US7705123B2 (en) 2010-04-27

Similar Documents

Publication Publication Date Title
DE69929019D1 (de) Mu-1, ein mitglied der zytokinrezeptor-familie
CY1107339T1 (el) Mu-1, μελος της οικογενειας υποδοχεα κυτοκινης
TR199600084A2 (tr) Sismanlamaya karsi proteinler.
NO905460L (no) Broennsonde.
DE3866823D1 (de) Fluggastbruecke.
ATE212055T1 (de) Östrogen-rezeptor
DE69019784D1 (de) Geschaltete Brückenanordnung.
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
EP0832978A3 (de) 3-Dehydrochinate Synthase
EP0879879A3 (de) Polypeptid-Deformylase 1 (Def1)
DE59000678D1 (de) Verlegbare bruecke.
EP0911409A3 (de) Deformylase
BR9408061A (pt) Sequência de dna codificando carboxipeptidase b pancreática de suiínos
MA21991A1 (fr) Elements de construction nouveaux .
IS4987A (is) PTX næm G prótein, framleiðsla þeirra og notkun
PT1045914E (pt) Proteinase svph1-8 humana especifica de testiculo
EP0927763A3 (de) Neues aroA
WO2000037634A3 (en) Novel polypeptides and nucleic acids encoding same
NO20011961D0 (no) PRV-1-genet og anvendelsen av dette
NO905542L (no) Tienobenzoksepin- og naftotiofenderivater, fremgangsmaate og mellomprodukter for fremstilling derav.
NL192121B (nl) Valblok.
EP0894862A3 (de) Neues CysS
EP0906957A3 (de) Lgt Polypeptid
EP0913479A3 (de) Adenin Glycosylase
NL1005484A1 (nl) Tuibrug.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DF-MP, 80333 MUENCHEN